NCT06904170
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06904170
Title Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma (ALICE)
Acronym ALICE
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNICANCER
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.